Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer
Abstract The androgen receptor signaling inhibitor enzalutamide (Enz) is one the primary therapeutic drugs for advanced prostate cancer (PCa). Nevertheless, most of patients ultimately develop resistance to Enz. Through an integrated analysis of CRISPR genome-wide and kinome-wide screens, coupled wi...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMC
2025-08-01
|
| Collection: | Biomarker Research |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1186/s40364-025-00822-x |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|